|Day Low/High||83.62 / 84.74|
|52 Wk Low/High||69.18 / 99.84|
John Flannery sees progress being made on GE's initiatives, but that is what I expected him to say.
Markets are down across the board in the first hour of trading. However, we are nicely off the lows of the day. Financials are bucking the early downward tilt of the market and are up today. This sector continues to benefit from slowly rising intere...
Is CVS's planned acquisition of Aetna just a reaction to Amazon's dive into healthcare? Here's what we know so far.
Entering GE too early has its costs, but there are ways to mitigate them.
European markets opened flat as investors await the European Central Bank meeting
European stock markets are priced almost to perfection ahead of an earnings deluge.
Biotech investors should keep a close eye on the progress in this huge potential market.
Stocks were under pressure again after Donald Trump made vague promises to lower drug prices.
There are nearly too many surging sectors to count.
Novartis has seen some very aggressive buying the past five months -- time to join in.
Some of Wall Street's biggest stocks are teetering on the edge of breakout territory this week. Here are five of them.
Reports from DuPont and Alibaba looked promising for the markets on Wednesday.
News of Intesa's potential takeover bid extended Generali's three-day gains to 15%.
As we await the jobs report, there is significant news across the biotech sector in the past 24 hours on some names I have mentioned in these pages. Amgen should be up nicely today after a judge stated that Regeneron would have to pull its PCKS9 inh...
A drug made by Ophthotech failed in a late stage trial, sending shares of the stock plunging.
U.S. stocks rose early Monday as investors parsed comments from oil officials in Iran and Iraq, hinting at a production cut at next week's OPEC meeting.
Novartis is entering into talks to purchase Amneal Pharmaceuticals in a deal that could value the company at $8 billion.
We have to ask: where is the cash flow to pay off the debt, if any important prices are rolled back?
Both it and Ligand Pharmaceuticals look significantly undervalued relative to their prospects.
Shares of the global healthcare company, Novartis, are down after it saw its profits fall in the second quarter.
You have to be impressed by the breadth of XNCR's pipeline and significant partnerships with major players.
Problems with mesh products and high leverage might scare away a potential buyer.
Pfizer scored the top spot in Interbrand Health's inaugural ranking of the top ten biopharmaceutical brands.
Valeant may have troubles, but Mallinckrodt is the poster child of price gouging.